Abstract: The present invention relates to compounds of formula (1): wherein R6 is —CONH2 or a —C(R?)(R?)(OH) group; R is a substituted phenyl or heteroaryl group; R7 is an optionally substituted aryl or heteroaryl group. Process for the preparation thereof and therapeutic use thereof.
Type:
Grant
Filed:
June 29, 2020
Date of Patent:
April 20, 2021
Assignee:
Sanofi
Inventors:
Jean-Christophe Carry, Fabienne Chatreaux, Stephanie Deprets, Olivier Duclos, Vincent Leroy, Sergio Mallart, Dominique Melon-Manguer, Maria Mendez-Perez, Fabrice Vergne
Abstract: Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.
Type:
Grant
Filed:
July 22, 2016
Date of Patent:
April 13, 2021
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Abstract: The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase).
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
April 13, 2021
Assignee:
PRECEDO PHARMACEUTICALS CO., LTD
Inventors:
Qingsong Liu, Jing Liu, Xixiang Li, Aoli Wang, Ziping Qi, Hong Wu, Jiaxin Wu, Wenchao Wang, Chen Hu, Cheng Chen, Li Wang, Beilei Wang
Abstract: Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
Type:
Grant
Filed:
April 1, 2019
Date of Patent:
April 13, 2021
Inventors:
Michael H. Rabinowitz, Mark D. Rosen, Kyle T. Tarantino, Hariharan Venkatesan
Abstract: The present invention provides methods for treating pruritus in a subject in need thereof comprising administering a therapeutically effective amount of a JAK inhibitor. Also provided are methods of intranasal administration of JAK inhibitors for use in treating pruritus.
Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Type:
Grant
Filed:
November 18, 2020
Date of Patent:
March 30, 2021
Assignee:
Pharmacyclics LLC
Inventors:
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Abstract: The present invention relates to a compound represented by formula I: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, nonalcoholic steatohepatitis (NASH), cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.
Type:
Grant
Filed:
November 13, 2017
Date of Patent:
March 16, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Dong-Ming Shen, Thomas H. Graham, Jinlong Jiang, Fa-Xiang Ding, Clare Tudge
Abstract: The present invention relates to solid state forms of a p-toluenesulfonic acid salt (PTSA) of the selective PI3K delta inhibitor (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one (TGR-1202). The present invention also relates to methods of preparing the same, pharmaceutical compositions containing them, and methods of treating a PI3K kinase mediated disease or disorder, such as cancer, by administering the same.
Abstract: Trisubstituted bicyclic heterocyclic compounds (e.g., pyridopyrimidinones) and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
Type:
Grant
Filed:
March 1, 2019
Date of Patent:
March 9, 2021
Assignee:
Infinity Pharmaceuticals, Inc.
Inventors:
Alfredo C. Castro, Catherine A. Evans, Martin R. Tremblay
Abstract: Disclosed are 9-deazaaadenine derivatives of the general formula (I) and pharmaceutically acceptable salts thereof, wherein A is OH or NH2, and B is H or NH2. Methods for treating and/or suppressing a Zika virus infection with the compounds disclosed are also provided. Pharmaceutical compositions comprising the disclosed compounds are also provided. Such pharmaceutical compositions may optionally contain one or more additional active agents.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
March 2, 2021
Assignee:
Biocryst Pharmaceuticals, Inc.
Inventors:
Yarlagadda S. Babu, Pravin L. Kotian, Shanta Bantia
Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
Type:
Grant
Filed:
June 12, 2017
Date of Patent:
March 2, 2021
Assignee:
NOVARTIS AG
Inventors:
Zhuoliang Chen, Jorge Garcia Fortanet, Rajesh Karki, Matthew J. Lamarche, Dyuti Majumdar, Lawrence Blas Perez, Martin Sendzik, Troy Douglas Smith, Fan Yang, Bing Yu
Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5? and R6 are described herein.
Type:
Grant
Filed:
July 19, 2019
Date of Patent:
March 2, 2021
Assignee:
Valo Early Discovery, Inc.
Inventors:
Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell, Darby Rye Schmidt, David Joseph Guerin, Justin Andrew Caravella, R. Bruce Diebold, Anna Ericsson, David R. Lancia, Jr.
Abstract: Compositions comprising derivatives of biopterin, useful for the treatment of traumatic brain injury, non-traumatic brain injury, elevated cranial pressure, and secondary brain injury.
Type:
Grant
Filed:
October 21, 2019
Date of Patent:
February 23, 2021
Assignee:
VASOPHARM GMBH
Inventors:
Peter Scheurer, Frank Tegtmeier, Reinhard Schinzel
Abstract: The disclosure relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, X1, X2, X3, n, and m are described herein.
Type:
Grant
Filed:
July 18, 2019
Date of Patent:
February 23, 2021
Assignee:
Valo Early Discovery, Inc.
Inventors:
Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell
Abstract: Compounds of formula (I): wherein: R1 is butoxy or methylbutoxy; R2 is a group having the structure: where n is an integer having a value of five; Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and R3 is hydrogen; or pharmaceutically acceptable salts thereof; and their use as vaccine adjuvants and in the treatment of various disorders.
Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
February 16, 2021
Assignee:
Cancer Research Technology Limited
Inventors:
Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J. T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
Abstract: Antiviral compounds comprising prodrugs with differing side chains derived from a tyrosine substance in the form of a tyrosine amide in which the amide substituent side chain is an alkyl ether, thioether, or alkene. Embodiments of the compounds have a range of effective lipophilicity values allowing variation in aqueous solubility, oral bioavailability, cell permeability and in vivo activation properties. The embodiments have promoieties derived from a single amino acid, which are expected to have low toxicity. The features described above also make possible a novel “precision medicine” approach to treatment of viral infections, whereby the prodrug variations can be exploited to match optimal activation of the prodrug to a given patient or strain of virus.
Type:
Grant
Filed:
October 31, 2017
Date of Patent:
February 16, 2021
Assignee:
University of Southern California
Inventors:
Charles E. McKenna, Boris A. Kashemirov, Jaijun Fan, Jinglei Lyu
Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.
Type:
Grant
Filed:
January 27, 2020
Date of Patent:
February 9, 2021
Assignee:
MannKind Corporation
Inventors:
Andrea Leone-Bay, Destardi Moye-Sherman, Bryan R. Wilson